Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Ongentys - withdrawal of application for variation to marketing authorisation

Ongentys - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

opicapone
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Ongentys
  • More information on Ongentys

Overview

BIAL withdrew its application for the use of Ongentys in the treatment of signs and symptoms of Parkinson’s disease.

The company withdrew the application on 12 March 2024.

Ongentys is a medicine used for treating adults with Parkinson’s disease, a progressive brain disorder that causes shaking and muscle stiffness, and slows movement.

Ongentys is used as an add-on to levodopa / DOPA decarboxylase inhibitors (DDCI) (other medicines for Parkinson’s disease) in patients who are having motor fluctuations in the control of their condition. Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due. Ongentys is used when these fluctuations cannot be treated with the standard levodopa-containing combinations alone.

Ongentys has been authorised in the EU since June 2016.

It contains the active substance opicapone and is available as capsules to be taken by mouth.

The company applied to extend the use of Ongentys to treat signs and symptoms of Parkinson’s disease; this means that its use in addition to levodopa / DDCI was to be extended to a broader group of patients, including patients with early stage Parkinson’s disease. It was no longer to be restricted to patients having (motor) fluctuations in the control of their condition. 

begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. The active substance in Ongentys, opicapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination. It enhances the effects of levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth. Opicapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catechol-O-methyl transferase (COMT). As a result, levodopa remains active for longer. This helps to improve the symptoms of Parkinson’s disease, such as stiffness and slowness of movement.

The company presented data from a study involving 355 patients with early stage Parkinson’s disease who received either Ongentys or placebo (a dummy treatment) in addition to levodopa / DDCI. Patients in the study had no signs of any motor complications (meaning fluctuations in their response to treatment or involuntary movements). The main measure of effectiveness was an improvement in motor symptoms as measured using a standard scale called Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). t

The application was withdrawn after the European Medicines Agency had evaluated the information from the company and had prepared questions for the company. After the Agency had assessed the company’s responses to the questions, there were still some unresolved issues.

Based on the review of the information and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had some concerns and its provisional opinion was that Ongentys could not have been authorised for the treatment of signs and symptoms of early stage Parkinson’s disease.

The Agency noted that the data on the effectiveness of Ongentys were not robust enough and indicated only a small effect of the medicine on MDS-UPDRS score and other measures of effectiveness. It was therefore not clear whether patients with mild symptoms of early stage Parkinson’s disease would benefit from treatment with Ongentys.

Therefore, at the time of the withdrawal, the Agency’s opinion was that, because effectiveness was not proven in the broader use, the benefits of Ongentys did not outweigh its risks.

In its letter notifying the Agency of the withdrawal of application, the company stated that they withdrew their application due to the need to conduct additional work to fully address the questions raised by the Agency.

The company informed the Agency that there are no consequences for patients in clinical trials using Ongentys.

If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

There are no consequences on the use of Ongentys in its authorised uses.

Questions and answers on the withdrawal of application to change the marketing authorisation for Ongentys (opicapone)

Reference Number: EMA/114749/2024

English (EN) (110.86 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View
Other languages (22)

български (BG) (162.69 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

español (ES) (137.23 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

čeština (CS) (159.58 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

dansk (DA) (138.06 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

Deutsch (DE) (140.94 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

eesti keel (ET) (135.44 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

ελληνικά (EL) (163.97 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

français (FR) (137.31 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

hrvatski (HR) (158.01 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

italiano (IT) (148.57 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

latviešu valoda (LV) (174.89 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

lietuvių kalba (LT) (159.48 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

magyar (HU) (159.4 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

Malti (MT) (169.43 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

Nederlands (NL) (138.44 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

polski (PL) (173.88 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

português (PT) (137.29 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

română (RO) (155.53 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

slovenčina (SK) (159.04 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

slovenščina (SL) (157.21 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

Suomi (FI) (134.83 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

svenska (SV) (136.42 KB - PDF)

First published: 22/03/2024Last updated: 18/09/2024
View

Key facts

Name of medicine
Ongentys
EMA product number
EMEA/H/C/002790
Active substance
opicapone
International non-proprietary name (INN) or common name
opicapone
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutical chemical (ATC) code
N04
Marketing authorisation holder
Bial - Portela Cª, S.A.
Date of issue of marketing authorisation valid throughout the European Union
24/06/2016
Date of withdrawal
12/03/2024

Documents

Withdrawal letter: Ongentys (WS2552-60)

English (EN) (167.77 KB - PDF)

First published: 22/03/2024
View

Withdrawal assessment report for Ongentys (WS2552-60)

Reference Number: EMA/CHMP/289566/2024

English (EN) (1.22 MB - PDF)

First published: 18/09/2024
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Ongentys

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024
22/03/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 April 2016
29/04/2016

More information on Ongentys

  • Ongentys
This page was last updated on 18/09/2024

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union